This segment focuses on the research, development, and clinical trials of vaccines targeting invasive pneumococcal disease (IPD) and pneumonia. The lead product candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials. Research and development activities include evaluating the safety, tolerability, and immunogenicity of VAX-24 in various patient populations, including adults and infants. The company utilizes advanced protein engineering and conjugation technologies to create high-fidelity vaccines. The goal is to provide broad protection against the most prevalent pneumococcal serotypes, addressing a significant unmet medical need and reducing the burden of antibiotic resistance. Market positioning involves competing with existing pneumococcal vaccines while offering a potentially superior product with broader coverage. Future opportunities include expanding the vaccine's indications and exploring combination therapies. Regulatory aspects involve seeking FDA approval and navigating the clinical trial process. Partnerships with Lonza for manufacturing are crucial for commercialization.

This segment encompasses the development of prophylactic vaccines to prevent bacterial infectious diseases beyond pneumococcal disease. This includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep, and VAX-XP, a vaccine designed to protect against emerging strains and address antibiotic resistance. Research and development activities involve identifying and targeting key bacterial pathogens, designing vaccine candidates, and conducting preclinical and clinical studies. The company employs protein engineering, conjugation, and other advanced technologies to create effective and safe vaccines. The therapeutic areas covered include various bacterial infections, with the aim of preventing disease and reducing the need for antibiotic treatments. Patient impact is significant, as these vaccines have the potential to prevent serious illnesses and reduce healthcare costs. Market positioning involves competing with existing vaccines and developing novel solutions for unmet needs. Future opportunities include expanding the pipeline to address other bacterial threats and exploring combination vaccines. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations may be necessary for manufacturing and commercialization.

This segment focuses on the development of VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. Research and development activities include identifying and characterizing the key antigens of the pathogen, designing the vaccine, and conducting preclinical and clinical studies to evaluate its safety and efficacy. The company utilizes protein engineering and other advanced technologies to create a vaccine that can prevent or treat periodontitis. The therapeutic area covered is oral health, with the aim of preventing and treating a common and debilitating disease. Patient impact is significant, as periodontitis can lead to tooth loss and other serious health problems. Market positioning involves addressing an unmet medical need in the field of oral health. Future opportunities include expanding the vaccine's indications and exploring combination therapies. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations may be necessary for manufacturing and commercialization.